Literature DB >> 30076176

Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.

Renate De Smedt1,2, Sofie Peirs1,2, Julie Morscio1,2, Filip Matthijssens1,2, Juliette Roels1,2,3, Lindy Reunes1,2, Beatrice Lintermans1,2, Steven Goossens1,2,4, Tim Lammens2,5, Nadine Van Roy1,2, Aurore Touzart6, Silvia Jenni7, Yi-Chien Tsai7, Federica Lovisa8, Lara Mussolin8, Valentina Serafin8, Filip Van Nieuwerburgh9, Dieter Deforce9, Anne Uyttebroeck10,11, Thomas Tousseyn12, Birgit Burkhardt13, Wolfram Klapper14, Barbara De Moerloose2,5, Yves Benoit2,5, Elizabeth Macintyre6, Jean-Pierre Bourquin7, Giuseppe Basso8, Benedetta Accordi8, Beat Bornhauser7, Jules Meijerink15, Peter Vandenberghe16,17, Pieter Van Vlierberghe18,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30076176      PMCID: PMC6312037          DOI: 10.3324/haematol.2018.199257

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy.

Authors:  Lori Muffly; Richard A Larson
Journal:  Transl Pediatr       Date:  2012-10

2.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.

Authors:  Guo Wei; David Twomey; Justin Lamb; Krysta Schlis; Jyoti Agarwal; Ronald W Stam; Joseph T Opferman; Stephen E Sallan; Monique L den Boer; Rob Pieters; Todd R Golub; Scott A Armstrong
Journal:  Cancer Cell       Date:  2006-09-28       Impact factor: 31.743

3.  Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping.

Authors:  Paula J P de Vree; Elzo de Wit; Mehmet Yilmaz; Monique van de Heijning; Petra Klous; Marjon J A M Verstegen; Yi Wan; Hans Teunissen; Peter H L Krijger; Geert Geeven; Paul P Eijk; Daoud Sie; Bauke Ylstra; Lorette O M Hulsman; Marieke F van Dooren; Laura J C M van Zutven; Ans van den Ouweland; Sjef Verbeek; Ko Willems van Dijk; Marion Cornelissen; Atze T Das; Ben Berkhout; Birgit Sikkema-Raddatz; Eva van den Berg; Pieter van der Vlies; Desiree Weening; Johan T den Dunnen; Magdalena Matusiak; Mohamed Lamkanfi; Marjolijn J L Ligtenberg; Petra ter Brugge; Jos Jonkers; John A Foekens; John W Martens; Rob van der Luijt; Hans Kristian Ploos van Amstel; Max van Min; Erik Splinter; Wouter de Laat
Journal:  Nat Biotechnol       Date:  2014-08-17       Impact factor: 54.908

4.  Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors.

Authors:  M van Lohuizen; S Verbeek; P Krimpenfort; J Domen; C Saris; T Radaszkiewicz; A Berns
Journal:  Cell       Date:  1989-02-24       Impact factor: 41.582

5.  Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia.

Authors:  Irene Homminga; Rob Pieters; Anton W Langerak; Johan J de Rooi; Andrew Stubbs; Monique Verstegen; Maartje Vuerhard; Jessica Buijs-Gladdines; Clarissa Kooi; Petra Klous; Pieter van Vlierberghe; Adolfo A Ferrando; Jean Michel Cayuela; Brenda Verhaaf; H Berna Beverloo; Martin Horstmann; Valerie de Haas; Anna-Sophia Wiekmeijer; Karin Pike-Overzet; Frank J T Staal; Wouter de Laat; Jean Soulier; Francois Sigaux; Jules P P Meijerink
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

6.  A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.

Authors:  Ying-Wei Lin; Zanna M Beharry; Elizabeth G Hill; Jin H Song; Wenxue Wang; Zuping Xia; Zhenhua Zhang; Peter D Aplan; Jon C Aster; Charles D Smith; Andrew S Kraft
Journal:  Blood       Date:  2009-11-23       Impact factor: 22.113

7.  AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.

Authors:  Erika K Keeton; Kristen McEachern; Keith S Dillman; Sangeetha Palakurthi; Yichen Cao; Michael R Grondine; Surinder Kaur; Suping Wang; Yuching Chen; Allan Wu; Minhui Shen; Francis D Gibbons; Michelle L Lamb; Xiaolan Zheng; Richard M Stone; Daniel J Deangelo; Leonidas C Platanias; Les A Dakin; Huawei Chen; Paul D Lyne; Dennis Huszar
Journal:  Blood       Date:  2013-12-20       Impact factor: 22.113

Review 8.  Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal.

Authors:  Nilesh Shah; Brendan Pang; Khay-Guan Yeoh; Shannon Thorn; Chien Shing Chen; Michael B Lilly; Manuel Salto-Tellez
Journal:  Eur J Cancer       Date:  2008-08-18       Impact factor: 9.162

9.  ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.

Authors:  Sofie Peirs; Filip Matthijssens; Steven Goossens; Inge Van de Walle; Katia Ruggero; Charles E de Bock; Sandrine Degryse; Kirsten Canté-Barrett; Delphine Briot; Emmanuelle Clappier; Tim Lammens; Barbara De Moerloose; Yves Benoit; Bruce Poppe; Jules P Meijerink; Jan Cools; Jean Soulier; Terence H Rabbitts; Tom Taghon; Frank Speleman; Pieter Van Vlierberghe
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

10.  A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.

Authors:  Jason M Foulks; Kent J Carpenter; Bai Luo; Yong Xu; Anna Senina; Rebecca Nix; Ashley Chan; Adrianne Clifford; Marcus Wilkes; David Vollmer; Benjamin Brenning; Shannon Merx; Shuping Lai; Michael V McCullar; Koc-Kan Ho; Daniel J Albertson; Lee T Call; Jared J Bearss; Sheryl Tripp; Ting Liu; Bret J Stephens; Alexis Mollard; Steven L Warner; David J Bearss; Steven B Kanner
Journal:  Neoplasia       Date:  2014-06-18       Impact factor: 5.715

View more
  4 in total

Review 1.  T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies.

Authors:  Valentina Cordo'; Jordy C G van der Zwet; Kirsten Canté-Barrett; Rob Pieters; Jules P P Meijerink
Journal:  Blood Cancer Discov       Date:  2020-11-24

2.  PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.

Authors:  James T Lim; Neha Singh; Libia A Leuvano; Valerie S Calvert; Emanuel F Petricoin; David T Teachey; Richard B Lock; Megha Padi; Andrew S Kraft; Sathish K R Padi
Journal:  Mol Cancer Ther       Date:  2020-08-04       Impact factor: 6.261

Review 3.  T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness.

Authors:  Valentina Bardelli; Silvia Arniani; Valentina Pierini; Danika Di Giacomo; Tiziana Pierini; Paolo Gorello; Cristina Mecucci; Roberta La Starza
Journal:  Genes (Basel)       Date:  2021-07-23       Impact factor: 4.096

Review 4.  The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL.

Authors:  Paniz Tavakoli Shirazi; Laura N Eadie; Susan L Heatley; Timothy P Hughes; David T Yeung; Deborah L White
Journal:  Br J Cancer       Date:  2019-12-03       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.